Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Income from Continuing Operations (2020 - 2023)

Historic Income from Continuing Operations for Therapeutics (RAPT) over the last 4 years, with Q4 2023 value amounting to -$33.2 million.

  • Therapeutics' Income from Continuing Operations fell 3596.25% to -$33.2 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$127.1 million, marking a year-over-year decrease of 4809.95%. This contributed to the annual value of -$127.1 million for FY2023, which is 4809.95% down from last year.
  • Latest data reveals that Therapeutics reported Income from Continuing Operations of -$33.2 million as of Q4 2023, which was down 3596.25% from -$33.9 million recorded in Q3 2023.
  • Therapeutics' 5-year Income from Continuing Operations high stood at -$12.4 million for Q2 2020, and its period low was -$33.9 million during Q3 2023.
  • Over the past 4 years, Therapeutics' median Income from Continuing Operations value was -$18.8 million (recorded in 2021), while the average stood at -$20.9 million.
  • As far as peak fluctuations go, Therapeutics' Income from Continuing Operations crashed by 1622.97% in 2022, and later plummeted by 5646.74% in 2023.
  • Over the past 4 years, Therapeutics' Income from Continuing Operations (Quarter) stood at -$12.7 million in 2020, then crashed by 40.79% to -$17.9 million in 2021, then plummeted by 36.27% to -$24.4 million in 2022, then tumbled by 35.96% to -$33.2 million in 2023.
  • Its Income from Continuing Operations was -$33.2 million in Q4 2023, compared to -$33.9 million in Q3 2023 and -$28.4 million in Q2 2023.